Abliva AB to Spotlight KL1333 for Mitochondrial Disease at Upcoming Virtual KOL Event

Abliva AB is hosting a virtual event on May 21, 2024, featuring Dr. Amel Karaa to discuss primary mitochondrial disease treatment and its lead program, KL1333. The event will include a presentation and live Q&A session, focusing on KL1333's potential in addressing unmet medical needs.

author-image
Aqsa Younas Rana
New Update
Abliva AB to Spotlight KL1333 for Mitochondrial Disease at Upcoming Virtual KOL Event

Abliva AB to Spotlight KL1333 for Mitochondrial Disease at Upcoming Virtual KOL Event

Abliva AB, a clinical-stage biopharmaceutical company focused on developing treatments for rare and severe primary mitochondrial diseases, is set to host, virtual, event on Tuesday, May 21, 2024, at 10:00 AM ET / 4:00 PM CET. The event will feature Dr. Amel Karaa, a renowned internist and clinical geneticist from Massachusetts General Hospital, who will discuss the current treatment landscape and unmet medical needs for patients with primary mitochondrial disease.

Why this matters: The development of effective treatments for rare and severe primary mitochondrial diseases has the potential to improve the quality of life for thousands of patients worldwide. A breakthrough in this area could also lead to a better understanding of the underlying causes of these diseases, paving the way for further research and innovation.

The KOL event will primarily focus on Abliva's lead program, KL1333, which has shown clinically meaningful, early signals of efficacy in mitochondrial disease patients. KL1333 is currently being evaluated in the potentially registrational Phase 2 FALCON trial, with an interim analysis expected mid-year 2024. The drug candidate has received Orphan Drug Designation (ODD) in both Europe and the U.S. and Fast Track designation in the U.S.

Dr. Amel Karaa brings extensive expertise to the event as a clinical researcher and trialist who has led and been involved in several national and international mitochondrial disease clinical trials at different stages of drug development. She is also the founder and director of the Mitochondrial Care Network (MCN) and has held various leadership positions in organizations focused on mitochondrial disease research.

Abliva's mission is to discover and develop medicines for the treatment of mitochondrial disease, a rare and often severe condition that occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects: KL1333 and NV354, an energy replacement therapy.

To register for the virtual KOL event, interested parties can visit the provided registration link. The formal presentation will be followed by a live question and answer session, allowing attendees to gain further insights into Abliva's progress and the potential of KL1333 in addressing the unmet needs of patients with primary mitochondrial disease.

Key Takeaways

  • Abliva to host virtual KOL event on May 21, 2024, featuring Dr. Amel Karaa.
  • Event to discuss current treatment landscape and unmet needs for primary mitochondrial disease.
  • Abliva's lead program, KL1333, shows early signals of efficacy in mitochondrial disease patients.
  • KL1333 has received Orphan Drug Designation and Fast Track designation in the U.S. and Europe.
  • Registration open for virtual event, featuring formal presentation and live Q&A session.